BEIJING, Jan. 12 (Xinhua) — Starting from May, diabetes patients in China will enjoy an average 48 percent drop in their medicine costs. The price cut will be effective on about 40 commonly used insulin products selected by the country’s centralized drug procurement program in November. The bulk-buying mechanism has so far benefited patients with hypertension, diabetes, hyperlipidemia, chronic hepatitis B, and other chronic or common diseases, with an average drug price cut of 53 percent.
Read the source article at English
2022-01-13 02:00:00
